Efficacy of Zolmitriptan (Zomig) in the treatment of migraines in adolescents
Study identifier:D1221C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study with Single-blind, Placebo-challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the treatment of Acute Migraine Headache in Adolescents.
Medical condition
migraine
Phase
Phase 3
Healthy volunteers
No
Study drug
Zolmitriptan, Placebo
Sex
All
Actual Enrollment
247
Study type
Interventional
Age
12 Years - 17 Years
Date
Study Start Date: 01 Sept 2003
Primary Completion Date: -
Study Completion Date: 01 Oct 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Zolmitriptan 5mg nasal spray Other Name: Zomig |
| Placebo Comparator: 2 | - |
